TransMedics Organ Care System - רווח נקי למניה אחת בשנים עשר החודשים האחרונים TMDX

TransMedics Group (TMDX) dominates the transplantation sector through its OCS system and robust R&D initiatives. The company is aggressively scaling its business by establishing its own aviation logistics. The current EPS TTM YoY growth rate visualizes the financial dynamics, where 55.30 indicates the current level. A steady cash flow is driven by inelastic demand for critical equipment, ensuring revenue stability.

Year-over-year EPS growth (TTM) measures the dynamics of net income per share over a rolling twelve-month period, allowing for an assessment of the actual scaling speed of business profitability. An analysis of the annual EPS TTM delta confirms the financial stability of TransMedics Group (TMDX), whose critical role in transplantology and humanitarian status ensure that profits remain protected from geopolitical shocks and trade restrictions.